Cargando…
Chemotherapy for advanced biliary tract carcinoma: A meta-analysis of randomized controlled trials
BACKGROUND: Although gemcitabine and platinum-based agents (GP) are currently regarded as the standard chemotherapy for advanced biliary tract cancer (BTC), the prognosis remains poor. Combinations with fluoropyrimidines and targeted therapy have demonstrated modest benefits. Therefore, we conducted...
Autores principales: | Chen, Lawrence, Chen, Chiehfeng, Yen, Yun, Tam, Ka-Wai |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5370815/ https://www.ncbi.nlm.nih.gov/pubmed/27537589 http://dx.doi.org/10.1097/MD.0000000000004584 |
Ejemplares similares
-
Network Meta-Analysis of Randomized Controlled Trials: Efficacy and Safety of UDCA-Based Therapies in Primary Biliary Cirrhosis
por: Zhu, Gui-Qi, et al.
Publicado: (2015) -
Predictive Factors of Biliary Tract Cancer in Anomalous Union of the Pancreaticobiliary Duct
por: Park, Jin-Seok, et al.
Publicado: (2016) -
The association between biliary tract inflammation and risk of digestive system cancers: A population-based cohort study
por: Tsai, Tsung-Yu, et al.
Publicado: (2016) -
Preoperative C-reactive protein-to-albumin ratio as a prognostic factor in biliary tract cancer: A systematic review and meta-analysis
por: Utsumi, Masashi, et al.
Publicado: (2023) -
A multicenter, randomized, double-blind trial comparing the efficacy and safety of TUDCA and UDCA in Chinese patients with primary biliary cholangitis
por: Ma, Hong, et al.
Publicado: (2016)